

# Rhabdomyosarcoma Drug-Europe Market Status and Trend Report 2013-2023

<https://marketpublishers.com/r/RC37715D3C5MEN.html>

Date: March 2018

Pages: 159

Price: US\$ 3,480.00 (Single User License)

ID: RC37715D3C5MEN

## Abstracts

### Report Summary

Rhabdomyosarcoma Drug-Europe Market Status and Trend Report 2013-2023 offers a comprehensive analysis on Rhabdomyosarcoma Drug industry, standing on the readers' perspective, delivering detailed market data and penetrating insights. No matter the client is industry insider, potential entrant or investor, the report will provide useful data and information. Key questions answered by this report include:

Whole Europe and Regional Market Size of Rhabdomyosarcoma Drug 2013-2017, and development forecast 2018-2023

Main market players of Rhabdomyosarcoma Drug in Europe, with company and product introduction, position in the Rhabdomyosarcoma Drug market

Market status and development trend of Rhabdomyosarcoma Drug by types and applications

Cost and profit status of Rhabdomyosarcoma Drug, and marketing status

Market growth drivers and challenges

The report segments the Europe Rhabdomyosarcoma Drug market as:

Europe Rhabdomyosarcoma Drug Market: Regional Segment Analysis (Regional Consumption Volume, Consumption Volume, Revenue and Growth Rate 2013-2023):

Germany

United Kingdom

France

Italy

Spain

Benelux

Russia

Europe Rhabdomyosarcoma Drug Market: Product Type Segment Analysis  
(Consumption Volume, Average Price, Revenue, Market Share and Trend 2013-2023):

ARI-4175

Celyvir

Crizotinib

Enoblituzumab

AT-69

Axitinib

Others

Europe Rhabdomyosarcoma Drug Market: Application Segment Analysis (Consumption  
Volume and Market Share 2013-2023; Downstream Customers and Market Analysis)

Research Center

Hospital

Clinic

Others

Europe Rhabdomyosarcoma Drug Market: Players Segment Analysis (Company and  
Product introduction, Rhabdomyosarcoma Drug Sales Volume, Revenue, Price and  
Gross Margin):

Bellicum Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Co

Celgene Corp

Eisai Co Ltd

Epizyme Inc

Exelixis Inc

Iproteos SL

Ipsen SA

MacroGenics Inc

NantKwest Inc

Novartis AG

Noxxon Pharma AG

Pfizer Inc

Taiho Pharmaceutical Co Ltd

Taiwan Liposome Company Ltd

Tarveda Therapeutics Inc

In a word, the report provides detailed statistics and analysis on the state of the industry; and is a valuable source of guidance and direction for companies and individuals interested in the market.

## Contents

### **CHAPTER 1 OVERVIEW OF RHABDOMYOSARCOMA DRUG**

- 1.1 Definition of Rhabdomyosarcoma Drug in This Report
- 1.2 Commercial Types of Rhabdomyosarcoma Drug
  - 1.2.1 ARI-4175
  - 1.2.2 Celyvir
  - 1.2.3 Crizotinib
  - 1.2.4 Enoblituzumab
  - 1.2.5 AT-69
  - 1.2.6 Axitinib
  - 1.2.7 Others
- 1.3 Downstream Application of Rhabdomyosarcoma Drug
  - 1.3.1 Research Center
  - 1.3.2 Hospital
  - 1.3.3 Clinic
  - 1.3.4 Others
- 1.4 Development History of Rhabdomyosarcoma Drug
- 1.5 Market Status and Trend of Rhabdomyosarcoma Drug 2013-2023
  - 1.5.1 Europe Rhabdomyosarcoma Drug Market Status and Trend 2013-2023
  - 1.5.2 Regional Rhabdomyosarcoma Drug Market Status and Trend 2013-2023

### **CHAPTER 2 EUROPE MARKET STATUS AND FORECAST BY REGIONS**

- 2.1 Market Status of Rhabdomyosarcoma Drug in Europe 2013-2017
- 2.2 Consumption Market of Rhabdomyosarcoma Drug in Europe by Regions
  - 2.2.1 Consumption Volume of Rhabdomyosarcoma Drug in Europe by Regions
  - 2.2.2 Revenue of Rhabdomyosarcoma Drug in Europe by Regions
- 2.3 Market Analysis of Rhabdomyosarcoma Drug in Europe by Regions
  - 2.3.1 Market Analysis of Rhabdomyosarcoma Drug in Germany 2013-2017
  - 2.3.2 Market Analysis of Rhabdomyosarcoma Drug in United Kingdom 2013-2017
  - 2.3.3 Market Analysis of Rhabdomyosarcoma Drug in France 2013-2017
  - 2.3.4 Market Analysis of Rhabdomyosarcoma Drug in Italy 2013-2017
  - 2.3.5 Market Analysis of Rhabdomyosarcoma Drug in Spain 2013-2017
  - 2.3.6 Market Analysis of Rhabdomyosarcoma Drug in Benelux 2013-2017
  - 2.3.7 Market Analysis of Rhabdomyosarcoma Drug in Russia 2013-2017
- 2.4 Market Development Forecast of Rhabdomyosarcoma Drug in Europe 2018-2023
  - 2.4.1 Market Development Forecast of Rhabdomyosarcoma Drug in Europe

2018-2023

2.4.2 Market Development Forecast of Rhabdomyosarcoma Drug by Regions

2018-2023

## **CHAPTER 3 EUROPE MARKET STATUS AND FORECAST BY TYPES**

3.1 Whole Europe Market Status by Types

3.1.1 Consumption Volume of Rhabdomyosarcoma Drug in Europe by Types

3.1.2 Revenue of Rhabdomyosarcoma Drug in Europe by Types

3.2 Europe Market Status by Types in Major Countries

3.2.1 Market Status by Types in Germany

3.2.2 Market Status by Types in United Kingdom

3.2.3 Market Status by Types in France

3.2.4 Market Status by Types in Italy

3.2.5 Market Status by Types in Spain

3.2.6 Market Status by Types in Benelux

3.2.7 Market Status by Types in Russia

3.3 Market Forecast of Rhabdomyosarcoma Drug in Europe by Types

## **CHAPTER 4 EUROPE MARKET STATUS AND FORECAST BY DOWNSTREAM INDUSTRY**

4.1 Demand Volume of Rhabdomyosarcoma Drug in Europe by Downstream Industry

4.2 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in Major Countries

4.2.1 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in Germany

4.2.2 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in United Kingdom

4.2.3 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in France

4.2.4 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in Italy

4.2.5 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in Spain

4.2.6 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in Benelux

4.2.7 Demand Volume of Rhabdomyosarcoma Drug by Downstream Industry in Russia

4.3 Market Forecast of Rhabdomyosarcoma Drug in Europe by Downstream Industry

## **CHAPTER 5 MARKET DRIVING FACTOR ANALYSIS OF RHABDOMYOSARCOMA DRUG**

5.1 Europe Economy Situation and Trend Overview

5.2 Rhabdomyosarcoma Drug Downstream Industry Situation and Trend Overview

## **CHAPTER 6 RHABDOMYOSARCOMA DRUG MARKET COMPETITION STATUS BY MAJOR PLAYERS IN EUROPE**

6.1 Sales Volume of Rhabdomyosarcoma Drug in Europe by Major Players

6.2 Revenue of Rhabdomyosarcoma Drug in Europe by Major Players

6.3 Basic Information of Rhabdomyosarcoma Drug by Major Players

6.3.1 Headquarters Location and Established Time of Rhabdomyosarcoma Drug Major Players

6.3.2 Employees and Revenue Level of Rhabdomyosarcoma Drug Major Players

6.4 Market Competition News and Trend

6.4.1 Merger, Consolidation or Acquisition News

6.4.2 Investment or Disinvestment News

6.4.3 New Product Development and Launch

## **CHAPTER 7 RHABDOMYOSARCOMA DRUG MAJOR MANUFACTURERS INTRODUCTION AND MARKET DATA**

7.1 Bellicum Pharmaceuticals Inc

7.1.1 Company profile

7.1.2 Representative Rhabdomyosarcoma Drug Product

7.1.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Bellicum Pharmaceuticals Inc

7.2 Boehringer Ingelheim GmbH

7.2.1 Company profile

7.2.2 Representative Rhabdomyosarcoma Drug Product

7.2.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Boehringer Ingelheim GmbH

7.3 Bristol-Myers Squibb Co

7.3.1 Company profile

7.3.2 Representative Rhabdomyosarcoma Drug Product

7.3.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Bristol-Myers Squibb Co

7.4 Celgene Corp

- 7.4.1 Company profile
- 7.4.2 Representative Rhabdomyosarcoma Drug Product
- 7.4.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Celgene Corp
- 7.5 Eisai Co Ltd
  - 7.5.1 Company profile
  - 7.5.2 Representative Rhabdomyosarcoma Drug Product
  - 7.5.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Eisai Co Ltd
- 7.6 Epizyme Inc
  - 7.6.1 Company profile
  - 7.6.2 Representative Rhabdomyosarcoma Drug Product
  - 7.6.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Epizyme Inc
- 7.7 Exelixis Inc
  - 7.7.1 Company profile
  - 7.7.2 Representative Rhabdomyosarcoma Drug Product
  - 7.7.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Exelixis Inc
- 7.8 Iproteos SL
  - 7.8.1 Company profile
  - 7.8.2 Representative Rhabdomyosarcoma Drug Product
  - 7.8.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Iproteos SL
- 7.9 Ipsen SA
  - 7.9.1 Company profile
  - 7.9.2 Representative Rhabdomyosarcoma Drug Product
  - 7.9.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Ipsen SA
- 7.10 MacroGenics Inc
  - 7.10.1 Company profile
  - 7.10.2 Representative Rhabdomyosarcoma Drug Product
  - 7.10.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of MacroGenics Inc
- 7.11 NantKwest Inc
  - 7.11.1 Company profile
  - 7.11.2 Representative Rhabdomyosarcoma Drug Product
  - 7.11.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of NantKwest Inc
- 7.12 Novartis AG

- 7.12.1 Company profile
- 7.12.2 Representative Rhabdomyosarcoma Drug Product
- 7.12.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Novartis AG
- 7.13 Noxxon Pharma AG
  - 7.13.1 Company profile
  - 7.13.2 Representative Rhabdomyosarcoma Drug Product
  - 7.13.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Noxxon Pharma AG
- 7.14 Pfizer Inc
  - 7.14.1 Company profile
  - 7.14.2 Representative Rhabdomyosarcoma Drug Product
  - 7.14.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Pfizer Inc
- 7.15 Taiho Pharmaceutical Co Ltd
  - 7.15.1 Company profile
  - 7.15.2 Representative Rhabdomyosarcoma Drug Product
  - 7.15.3 Rhabdomyosarcoma Drug Sales, Revenue, Price and Gross Margin of Taiho Pharmaceutical Co Ltd
- 7.16 Taiwan Liposome Company Ltd
- 7.17 Tarveda Therapeutics Inc

## **CHAPTER 8 UPSTREAM AND DOWNSTREAM MARKET ANALYSIS OF RHABDOMYOSARCOMA DRUG**

- 8.1 Industry Chain of Rhabdomyosarcoma Drug
- 8.2 Upstream Market and Representative Companies Analysis
- 8.3 Downstream Market and Representative Companies Analysis

## **CHAPTER 9 COST AND GROSS MARGIN ANALYSIS OF RHABDOMYOSARCOMA DRUG**

- 9.1 Cost Structure Analysis of Rhabdomyosarcoma Drug
- 9.2 Raw Materials Cost Analysis of Rhabdomyosarcoma Drug
- 9.3 Labor Cost Analysis of Rhabdomyosarcoma Drug
- 9.4 Manufacturing Expenses Analysis of Rhabdomyosarcoma Drug

## **CHAPTER 10 MARKETING STATUS ANALYSIS OF RHABDOMYOSARCOMA DRUG**



- 10.1 Marketing Channel
  - 10.1.1 Direct Marketing
  - 10.1.2 Indirect Marketing
  - 10.1.3 Marketing Channel Development Trend
- 10.2 Market Positioning
  - 10.2.1 Pricing Strategy
  - 10.2.2 Brand Strategy
  - 10.2.3 Target Client
- 10.3 Distributors/Traders List

## **CHAPTER 11 REPORT CONCLUSION**

## **CHAPTER 12 RESEARCH METHODOLOGY AND REFERENCE**

- 12.1 Methodology/Research Approach
  - 12.1.1 Research Programs/Design
  - 12.1.2 Market Size Estimation
  - 12.1.3 Market Breakdown and Data Triangulation
- 12.2 Data Source
  - 12.2.1 Secondary Sources
  - 12.2.2 Primary Sources
- 12.3 Reference

## I would like to order

Product name: Rhabdomyosarcoma Drug-Europe Market Status and Trend Report 2013-2023

Product link: <https://marketpublishers.com/r/RC37715D3C5MEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/RC37715D3C5MEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970